These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 10880052)

  • 1. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.
    Mihara M; Tan I; Chuzhin Y; Reddy B; Budhai L; Holzer A; Gu Y; Davidson A
    J Clin Invest; 2000 Jul; 106(1):91-101. PubMed ID: 10880052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus.
    Wang X; Huang W; Mihara M; Sinha J; Davidson A
    J Immunol; 2002 Feb; 168(4):2046-53. PubMed ID: 11823542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus.
    Wang X; Huang W; Schiffer LE; Mihara M; Akkerman A; Hiromatsu K; Davidson A
    Arthritis Rheum; 2003 Feb; 48(2):495-506. PubMed ID: 12571860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
    Via CS; Rus V; Nguyen P; Linsley P; Gause WC
    J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig.
    Chu EB; Hobbs MV; Wilson CB; Romball CG; Linsley PS; Weigle WO
    J Immunol; 1996 Feb; 156(3):1262-8. PubMed ID: 8558006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice.
    Zhou YB; Ye RG; Li YJ; Xie CM; Wu YH
    Autoimmunity; 2008 Aug; 41(5):395-404. PubMed ID: 18568645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of murine lupus with CTLA4Ig.
    Finck BK; Linsley PS; Wofsy D
    Science; 1994 Aug; 265(5176):1225-7. PubMed ID: 7520604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice.
    Merino R; Iwamoto M; Fossati L; Izui S
    J Immunol; 1993 Dec; 151(11):6509-16. PubMed ID: 7902378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA4Ig alters the course of autoimmune disease development in Lyn-/- mice.
    Oracki SA; Tsantikos E; Quilici C; Light A; Schmidt T; Lew AM; Martin JE; Smith KG; Hibbs ML; Tarlinton DM
    J Immunol; 2010 Jan; 184(2):757-63. PubMed ID: 19966213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide.
    Ferrera F; Hahn BH; Rizzi M; Anderson M; Fitzgerald J; Millo E; Indiveri F; Shi FD; Filaci G; La Cava A
    Arthritis Rheum; 2007 Jun; 56(6):1945-53. PubMed ID: 17530718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.
    Daikh DI; Finck BK; Linsley PS; Hollenbaugh D; Wofsy D
    J Immunol; 1997 Oct; 159(7):3104-8. PubMed ID: 9317105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of immune function by calorie restriction and cyclophosphamide treatment in lupus-prone NZB/NZW F1 mice.
    Sun D; Krishnan A; Su J; Lawrence R; Zaman K; Fernandes G
    Cell Immunol; 2004 Mar; 228(1):54-65. PubMed ID: 15203320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
    Sharabi A; Azulai H; Sthoeger ZM; Mozes E
    Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice.
    Zhang Y; Saha S; Rosenfeld G; Gonzalez J; Pepeljugoski KP; Peeva E
    J Rheumatol; 2010 Aug; 37(8):1646-57. PubMed ID: 20551107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble human CD83 ameliorates lupus in NZB/W F1 mice.
    Starke C; Steinkasserer A; Voll RE; Zinser E
    Immunobiology; 2013 Nov; 218(11):1411-5. PubMed ID: 23886695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig.
    Jooss K; Turka LA; Wilson JM
    Gene Ther; 1998 Mar; 5(3):309-19. PubMed ID: 9614550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive expression of murine CTLA4Ig from a recombinant adenovirus vector results in prolonged transgene expression.
    Schowalter DB; Meuse L; Wilson CB; Linsley PS; Kay MA
    Gene Ther; 1997 Aug; 4(8):853-60. PubMed ID: 9338015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defects in the regulation of anti-DNA antibody production in aged lupus-prone (NZB x NZW)F1 mice: analysis of T-cell lymphokine synthesis.
    Sato MN; Minoprio P; Avrameas S; Ternynck T
    Immunology; 1995 May; 85(1):26-32. PubMed ID: 7635519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class-specific regulation of anti-DNA antibody synthesis and the age-associated changes in (NZB x NZW)F1 hybrid mice.
    Sekigawa I; Okada T; Noguchi K; Ueda G; Hirose S; Sato H; Shirai T
    J Immunol; 1987 May; 138(9):2890-5. PubMed ID: 2952727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.